1. Bliiher M., Engeli S, Rioting N, Berndt J, Fasshauer M et al. Dysregulation of the Peripheral and Adipose Tissue Endocannabinoid System in Human Abdominal Obesity. Diabetes , 2006; Vol. 55: 3053-3060.
2. Carey VJ. Walters ЕЕ, Colditz GA et al. Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women. The Nurses' Health Study. Am J Epidemiol 1997; 145: 614-9. 
3. Despres JP et al. Effects of rimonabant on metaboli c risk factors in overweight patients with dyslipidaemia. N Engl J Med 2005; 353: 2121-2134.
4. Dospres J-P, Golay A, and Lars Sjostrorn for the Rimonabant in Obesity-Lipids Study Group. Effects of Rjmonabant on Metabolic Risk Factors in Overweight Patients with Dyslipidemia. N Eng J of Med., 2005,353: 2121-2134. 
5. DuPont RL. Examining the debate on the use of medical marijuana users. Proc Assoc Am Physicians. 1999; 111: 166-172.
6. Fotd ЈS el al. Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults: findings from the National Health and Nutrition Examination Survey, 1999 to 2000. Circulation 2003: 107(17):2185-9.
7. Goldstein D. Benefical health effects of modest weught loss Int J Obesity 1992, 16: 397-415.
8. Luc Van Gaal, Xavier Pi-Sunyer, Jeao-Pierre Despres, Christine McCarthy and Andre Schecn. Efficacy and Safety of Rimonabant for Improvement of Multiple Cardiometabolic Risk Factors in Overweight/Obese Patients. Pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care, 2008, 31: S229-S240. 
9. Mary Lynn Mathre. Therapeutic Cannabis. A patient advocacy issue. American Journal of Nursing, 2001, Vol. 101, No. 4, pp. 61-69.
10. Nissen S., Nicholls S., Wolski K et al. Effect of Rimonabant on Progression of Atherosclerosis in Patients With Abdominal Obesity and Coronary Artery Disease. The STRADIVARIUS Randomized Controlled Trial. JAMA, 2008, Vol.299. 1547-1560.
11. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R: The emerging role of the endocannablnoid system in endocrine regulation and energy balance Endocr Rev 2006, 27:73-100. 
12. O'Riordan M. RIO-Diabetes: Rimonabant effective in patients with type 2 diabetes. www.theheart.org.
13. Scheen A et al. Rimonabant improves cardiometablic risk factors in overweight, obese patients with type 2 diabetes irrespective of background oral antidiabetic therapy (metformin or sulfonylureas). ADA 2006.
14. Wang Y et al. Comparison of abdominal adiposityand overall obesity in predicting risk of type 2 diabetes among men. Am J Clin Nutr 2005; 81: 555-563.
15. Wilson Rl, Nicholl RA Endocannabinoid signaling in the brain. Science 2002; 296: 678-682.
16. Di Marzo V, BIfuIco M, De Prtrocellis I. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004; 3: 771-84.
17. Cola D, Marsicano G, Tschop M, et al.The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003; 112:423-31.
18. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946-9.
19. Hanus L, Abu-Lafi S, Fride E, et al. 2-Arachidonyl glyeeryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Pruc Natl Acad Sci USA 2001; 98: 3662-5.
20. Hewlett AC, Earth F, Bonner TI, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54: 161-202.
21. Fagotto U, Pasquali R. Fighting obesity and associated risk factors by antagonising cannabinoid type 1 recep¬tors. Lancet 2005; 365: 1363-4.
22. Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosd 2005; 8: 585-9.
23. Sugiura X Kondo S, Sukagawa A, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoidreceptor ligand in brain. Biochem Biophys Res Commun 1995; 215: 89-97.
24. Gaoni Y, Mechoulam R. Hashish III: isolation, struc¬ture and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964; 86: 1646-7.
25. Despres J-P, Lemieux I, Alineras N. Contribution of CBJ blockade to the management of high-risk abdom¬inal obesity. Part II: The Endocannabinoids and Regu¬lation of Energy Balance; The Endocannabinoid System: a Target for Anti-Obesity Drugs. Int J Obes 2006; 30: S44-52.
26. Van Gaal LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid-1 receptor Blоскeг rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO- Europe study. Lancet 2005; 365: 1389-97.
27. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997; 74: 129-80.
28. Cote M, Mauriege P, Bergeron J, et al. Adiportectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid level in men. J Clin Endocrinol Metab 2005; 90: 1434-9.

А.А.Александров